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In Switzerland, the PMWS epizooty started in 2003 and reached the zenith in 2008. 
After mass vaccination of piglets in the third week of life in 2008/09, PMWS 
decreased dramatically. PCV2-specific antibody profiles of 200 randomly selected 
serum samples of slaughter pigs of the preepizootic stage (1996/97) were compared 
with 200 serum samples collected nearly at the top of the epizooty (2006) and with 
samples collected in 2011, two years after after mass vaccination. In 1996/97, PCV2 
antibody titres were low throughout Switzerland with modest positive samples. In 
2006, almost all of the samples were positive with much higher titres. In 2011, 
antibody titres decreased to a level as low as the preepizootic level. Additionally, 50 
samples of each period were analyzed for IgM concentration. Only two samples of 
the year 2006 contained IgM antibodies.  
 







Die Schweizer PMWS Epizootie begann im Jahre 2003 und erreichte ihren Zenit im 
2008. Nach der Einführung der flächendeckenden Impfung der Ferkel in der 3. 
Lebenwoche in den Jahren 2008/09 reduzierte sich die Anzahl der PMWS – Fälle 
drastisch. In der vorliegenden Arbeit wurden PCV2-spezifische Antikörpertiter von 
200 zufällig ausgewählten Schlachtschweineseren der Präepizootie (1996/97) mit je 
200 Serumproben aus den Jahren 2006, fast auf dem Höhepunkt der Epizootie, und 
2011, nach der flächendeckenden Impfung, verglichen. In den Jahren 1996/97 hatten 
wenige Tiere einen positiven PCV2 – Antikörpertiter und die Titer waren tief. In 2006 
waren fast alle Proben positiv auf PCV2 – Antikörper und die Antikörpertitrer waren 
um ein Vielfaches höher als zuvor. Im Jahre 2011 sanken die Titer wieder fast auf 
das präepizootische Niveau ab. 
In einer zweiten Untersuchung wurden je 50 Serumproben aller drei Zeitpunkte auf 
das Vorhandensein von anti PCV2-IgM Antikörper analysiert. Zwei Proben aus dem 
Jahr 2006 waren positiv für IgM. 
 






Porcine Circovirus Type 2 (PCV2) is one of the most significant pathogen in pig 
production worldwide. The virus is involved in several syndromes summarized as 
porcine circovirus type 2 diseases (PCVDs) (Segalés et al., 2005). Postweaning 
multisystemic wasting syndrome (PMWS), nowadays termed as porcine circovirus 
type 2–systemic diseases (PCV2-SD), was the most relevant and devastating 
disease, described first in Canada by Harding and Clark in 1997. Since then, PCV2-
SD has spread worldwide, potentially among the trade ways (Segalés et al., 2013). 
However, PCV2 is the causative agent for PCVDs and the synergy with other factors 
is extensively discussed from different points of view involving other infectious 
pathogens (Opriessnig et al., 2007; Segalés et al., 2005), bad husbandry and 
management (Woodbine et al., 2007) and other stress-factors (Baumgartner et al., 
2012) respectively immunosuppression (Klausmann et al., 2015). PCV2 is ubiquitous 
and can be isolated from both healthy and diseased pigs (Allan and Ellis, 2000). 
Evenmore, PCV2-DNA could be detected in 100% of the fetuses of cinical healthy 
sows slaughterd at 80 – 105 gestation day (Sydler et al., 2016). 
Thus, PCV2-specific antibodies are ubiquitous and therefore PCV2-serology has no 
diagnostic value. However, analysis of seroprofiles is useful to follow maternal 
antibody titres, to fix the time of infection or seroconversion and to measure the 
efficacy of vaccination.  
PCV2-SD affected and healthy animals seroconvert at the same time point or 
later and PCV2-specific IgGs are slightly lower in PCV2-SD-affected pigs compared 
to healthy pigs (Meerts et al., 2006). The major immunological differences are a low 
level of neutralizing antibodies, high production of IL-10 and poor IFN- response in 
sick pigs (Meerts et al., 2006; Meng, 2013). An increased virus replication in affected 
pigs was observed (Meerts et al., 2005). PCV2-SD affected pigs seem to be unable 
to recognize or to produce antibodies against the epitopes that are involved in the 
virus neutralization (Meerts et al., 2006). In asymptomatic pigs, the maternal 
antibodies decrease from 3rd to 11th week of life and the naturally acquired PCV2-
specific antibodies increase until slaughtering (Ramamoorthy and Meng, 2008).  
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Experimental vaccination studies have shown elevated PCV2-neutralizing 
antibodies (Fort et al., 2007; Solis Worsfold et al., 2015), significantly shorter and 
lower viremia in vaccinated than in unvaccinated pigs (Cline et al., 2008; Fort et al., 
2008) and a higher proportion of CD4(+) CD8(+) INF-(+) lymphocyte subsets in 
vaccinated piglets (Oh et al., 2014). Viral load reduction and lower percentage of 
infected pigs are perceived as corner stones in order to control the clinical 
manifestations (Feng et al., 2014). In subclinically infected herds, slaughter pigs 
showed higher PCV2-specific antibody titres compared to pigs vaccinated with a 
subunit vaccine in the third week of life (Fachinger et al., 2008; Kixmöller et al., 2008; 
Solis Worsfold et al., 2015). The authors explained this finding with shorter and lower 
viremia levels in vaccinated pigs, avoiding an extensive PCV2-specific antibody 
production. Vaccination against PCV2 is enormously effective to prevent clinical 
manifestations, but is not able to avoid PCV2 infection (Fort et al., 2009). PCV2 
vaccines are used either in piglets at 3 - 4 weeks of age or in sows in the late stage 
of gestation to enrich maternal antibodies in the colostrum for passive immunization. 
Nowadays, subunit piglet vaccines containing the capsid protein of PCV2a are the 
most frequently used worldwide. Vaccination studies demonstrated that vaccination 
with subunit vaccines are activating both humoral and cellular immune response 
(Martelli et al., 2011; Fort et al., 2012), in spite of the fact that all fetal thymi are 
latently infected with PCV2 (Sydler et al., 2016).  The immune system of vaccinated 
pigs recognizes a large polypeptide fragment of the capsid protein (CP 43-233) and 
this region has a strong virus neutralizing activity (Trible et al., 2011). This may be 
the reason why only vaccinated pigs are protected against disease in a challenge 
model (Trible et al., 2011). In contrast, antibodies of diseased pigs are mainly 
directed against an immunodominant oligopeptide of the capsid protein (CP 169-
180), without virus neutralizing activity (Trible et al., 2012). It has been suggested 
that the level of neutralizing PCV2-specific antibodies is an indicator of protection 
against PCVDs (Fort et al., 2007; Trible et al., 2012).  
 
In Switzerland, PCV2-SD was described first by Borel et al. in 2001. However, 
it was shown retrospectively that PCV2 was present in the Swiss pig population at 
least as early as 1979 (Wiederkehr et al., 2009). In a prospective study from 2001/02, 
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PMWS was not the main reason for wasting in weaned piglets (Staebler et al., 2004). 
From 72 wasting piglets out of 26 farms only 4 pigs (5%) showed histologically typical 
PMWS lesions and 11 showed moderate IHC positivity. However, 70% had PCV2-
specific antibodies measured by IPMA (Staebler et al., 2004). In spite of the high 
sero-prevalence, PMWS was diagnosed more and more in Switzerland since 2003, 
first in regions of Switzerland with high pig density (Welti et al., 2012). The sudden 
onset of the epizooty was explained with a genetic shift from PCV2a to PCV2b-CH 
subtype (Wiederkehr et al., 2009). It should be mentioned, that then as now, 
Switzerland is free of PRRSV as well as enzootic pneumonia and actinobazillosis 
(Sidler et al., 2015). Therefore, a respiratory disease complex did not exist in 
Switzerland during the PCV2 epizooty. Since the introduction of piglet vaccination in 
the third week of life with a one-shot piglet vaccine in 2008, PMWS has been 
decreased dramatically. Today about 90% of the piglets are vaccinated and PMWS 
has nearly disappeared.  
The aim of this study was to examine PCV2 specific antibody titre profils in the 
Swiss pig population in different regions with different size of pig farms at the pre-
epizootic, epizootic and post-epizootic period. 
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2 Material and Methods 
2.1 Materials 
600 serum samples of slaughter pigs of the serum database of the Institute of Virus 
and Immunprophylaxis (IVI), Mittelhäusern, Switzerland, were analized, 200 samples 
of each time points of the years 1996/97, before the epizooty, during the epizooty in 
2006, but before mass vaccination and 2011, two years after piglet mass vaccination. 
The serum samples were chosen randomly and according to the pig densitiy and 
farm size in the various regions in Switzerland. The regions are characterized as 
follow: Canton Berne (small farm size), Canton Lucerne (moderate farm size and 




2.2.1 Serological examinations 
A competitive ELISA (SERELISA® PCV2 Ab Mono Blocking Systems, Synbiotics 
Corporation Europe SAS, Lyon) was used for antibody (IgG) detection. The 
completion of the test, data analysis and transformation of the data into ELISA units 
(EU) were done according to the manufacturer’s instructions and a published 
reference (Guillossou et al., 2008). We supplemented the assay with two additional 
controls to the sera dilutions suggested by the manufacturer. First, we used an 
additional positive and negative control serumg to check plate antigen coating 
homogeneity. Secondly, we normalized S-values among individual plates with the aid 
of a known serum (Kurmann et al., 2011). Immunoglobulin M (IgM) was measured 
using INGEZIM CIRCOVIRUS IgG/IgM (Ingenasa, Madrid), a capture 
immunoenzymatic assay specific IgM antibody detection to PCV2. For the IgM 
analysis, 50 samples of each period were randomly chosen and tested. 
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2.2.2 Statistics 
Data editing was done using Excel (Microsoft Inc.) and the statistical analyses were 
done using Stata Software (StataCorp., 2011; Stata Statistical Software: Release 12; 
College Station, TX, USA: StataCorp LP). Analyses were carried out with ANOVA 
(Bonferroni corrected) and Chi-Square-Test. A p-value of ≤ 0.05 was considered as 
significant. 
To compare the different titre heights we put two arbitrary thresholds at titre heights 





3.1 Distribution of PCV2 antibodies in Switzerland in 1996/97, 2006 and 2011 
Development of the PCV2 specific antibody titres between the different time points is 
shown in figure 1. The titres varied heavily between the different periods.  
In 1996/97, 43% of the samples had an antigen titre above 1000 EU. Only 7% 
of the samples reached titres >8000 EU. In 2006 the number of titres >1000 EU rose 
from 43% to 84% and 37% of the samples showed titres >8000 EU (p<0.05). After 
mass vaccination of the piglets in 2011, the numbers of IgG positive serum samples 
decreased significantly from 84% to 40% as well as the number of samples with titres 
>8000 EU from 37% to 10% (p<0.05). However there is no statistically significant 
difference between the data from 1996/97 and 2011 (p=0.83). 
Two of the samples of 2006 were positive for anti-PCV2 IgM antibodies; all the 





Figure 1: Distribution of PCV2-specific antibodies in Switzerland in 1996/97, 2006 








3.2 Regional distribution of anti-PCV2 IgG antibodies in 1996/97, 2006 and 2011 
The regional differences mirror the Swiss wide results and are shown in table 1 and 
figure 2 and 3.  All the regions have statistically significant differences in titre height 
between 1996/97 and 2006 and also 2006 and 2011 (p<0.05). There are no 
statistically significant differences comparing 1996/97 and 2011. In the different years, 
there are no statistically significant differences comparing the various regions. 
 
Table 1: Distribution of the antibody titres in the different regions of Switzerland in the 
three different years. 
Region n= samples 
 
1996/97 
>1000 / >8000 EU (%) 
2006 
>1000 / >8000 EU (%) 
2011 
>1000 / >8000 EU (%) 
Canton Lucerne  60 40 / 3 87 / 43 28 / 8 
Canton Berne 35 54 / 9 86 / 46 44 / 9 
Eastern Switzerland 52 42 / 4 79 / 27 45 / 8 
Rest of Switzerland 53 40 / 13 83 / 28 42 / 12 
Figure 2: ANOVA results of the titre comparison (the 4 regions of Switzerland, 





Figure 3: IgG Antibody titres from different regions in Switzerland at the preepizootic 
stage (1996/97), nearly at the zenith of the PMWS epizooty (2006) and two years 








In the Swiss pig population, the number of PCV2-seropositive pigs as well as 
antibody titres increased significantly between 1996/1997 and 2006. This 
augmentation is due to an increased and prolonged virus excretion and extended 
viremia of sick pigs.  As a result, infection pressure has risen with the accelerated 
number of diseased pigs during the epizooty. Two years after mass vaccination of 
piglets in the third week of life, the number of seropositive pigs and the titre returned 
to the pre-epizootic level. It can be speculated, that after piglet vaccination in the third 
week of life, PCV2-specific IgG decrease strongly till slaughtering and the vaccination 
is not protecting as long as the vaccine manufacturers described. However, own 
studies have indicated that after vaccination in the third week of life, the number of 
seroconverted pigs and the antibody titres of 30 kg pigs were not different from those 
of 105 kg body weight (data not shown). We also tested 50 randomly selected sera 
from each of the 3 time-intervals for PCV2-specific-IgM. Only two pigs of the year 
2006 were IgM positive, suggesting that none of the vaccinated pigs of 2011 had a 
late PCV2-reinfection, despite low PCV2-specific-IgG-antibodies. 
 There was no statistical significant difference in the different regions of 
Switzerland regarding the number of positive and height of antibody titres. 
Low antibody response as well as lack of antibody development does not correlate 
with lack of protection (Kekarainen et al., 2010). Fenaux et al. (2004) demonstrated 
that not all vaccinated piglets seroconverted after vaccination, but they still were 
protected in a challenge model. Several studies have shown that vaccination in the 
3rd week of life induces both, humoral and cell-mediated immune response, which 
protects the piglets from disease. PCV2 specific interferon--secreting cells were 
increased 3 weeks after vaccination. Interferon--secreting cells play an important 
role in the viral clearance (Fort et al., 2009; Martelli et al., 2011).  Before vaccination 
more than 70% of the piglets exhibited >107 DNA copies/ml blood, while in all 
vaccinated pigs the virus load was lower than 106 DNA copies (Martelli et al., 2011).  
Normally, the first contact with a pathogen or the first application of the vaccine leads 
to a stimulation of memory cells and very few IgG-secreting plasma cells. However, a 
second contact or a second vaccination leads to a massive increase of IgG. The aim 
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of a one-shot-vaccination is to stimulate the immune system in all vaccinated 
animals. The booster, irrespectively, the stimulation of the IgG-secreting plasma cells 
has to be done by the ubiquitously occurring PCV2.  
 Inducing PCV2 neutralizing antibodies, vaccination leads to a significant but 
an incomplete virus clearance (Fort et al., 2008; Fort et al., 2009; Martelli 2011; Trible 
et al., 2011) and consequently to a reduction of infection pressure. In a six-year 
lasting vaccination program in the USA, the number of PCV2 viremic finisher pigs 
dropped from 82.6% in 2006 to 17.2% in 2012 and PCV2 negative finisher farms 
increased from 0.5 to 52.1% (Dvorak et al., 2016). There was a 22-fold decrease in 
median viral levels and the percentage of PCV2-specific antibody positive pigs 
showed a marked decrease from 78.8% in 2006 to 19% in 2006 (Puvanendiran et al., 
2011). The return to the pre-epizootic level considering PCV2 antibody levels two 
years after mass vaccination can be explained by the hypothesis, that infection 
pressure is not strong enough to stimulate the IgG-producing plasma cells.  As a 
result of long lasting mass vaccination, in Switzerland PCV2-SD has nearly 
disappeared, in accordance to Afgahah et al. (2016). In case of vaccination, virus 
shedding is decreased significantly and therefore it can be speculated that long 
lasting vaccination may lead to a PCV2-elimination over time.  
 
In conclusion, a long lasting vaccination programme is able to reduce infection 
pressure prominently. With commercial ELISA methods, the total amount of PCV2 
specific IgG can be measured and they cannot be distinguished from neutralizing 
antibodies. Nevertheless, these ELISA are suitable for surveillance of infection 
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